Urology
Volume 74, Issue 4 , Pages 726-730 , October 2009

Focal Therapy for Prostate Cancer Is a Reasonable Treatment Option in Properly Selected Patients

Received 29 November 2008 ,Accepted 11 February 2009.

References 

  1. Meiers I, Waters DJ, Bostwick DG. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology. 2007;70:3–8
  2. Polascik TJ, Mayes JM, Sun L, et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate. 2008;68:1380–1386
  3. Bastacky SI, Wojno KJ, Walsh PC, et al. Pathological features of hereditary prostate cancer. J Urol. 1995;153:987–992
  4. Yoon GS, Wang W, Osunkoya AO, et al. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol. 2008;179:2203–2206
  5. Mouraviev V, Mayes JM, Polascik TJ. Pathological background and its clinical implications for focal therapy of early detected prostate cancer. Nat Clin Pract Urol. (in press).
  6. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–2149
  7. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359–2364
  8. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46–50
  9. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 2006;176:2432–2437
  10. Brame RS, Zaider M, Zakian KL, et al. Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys. 2009;74:110–114
  11. Barzell WE, Melamed MR. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate—a 4-year experience. Urology. 2007;70:27–35
  12. Onik G, Narayan P, Vaughan D, et al. Focal “nerve-sparing” cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology. 2002;60:109–114
  13. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96:999–1004
  14. Patel AR, Jones JS, Rabets J, et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology. 2004;63:87–89
  15. Jones JS. Saturation biopsy for detecting and characterizing prostate cancer. BJU Int. 2007;99:1340–1344
  16. Patel AR, Jones JS, Zhou M, et al. Parasagittal biopsies are more important as part of an initial biopsy strategy than as part of a repeat biopsy strategy: observations from a unique population. Prostate Cancer Prostatic Dis. 2007;10:352–355
  17. Lambert EH, Bolte K, Masson P, et al. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69:1117–1120
  18. Bahn DK, Silverman P, Lee F, et al. Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol. 2006;20:688–692
  19. Onik G. Rationale for a “Male Lumpectomy”, a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol. 2008;31:98–106
  20. Ellis DS, Manny TB, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology. 2007;70:9–15
  21. Onik G, Vaughan D, Lotenfoe R, et al. The “male lumpectomy”: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol. 2008;26:500–505
  22. Ellis DS, Jones JS, Pisters L, et al. Subtotal/partial gland prostate cryoablation: results of 341 patients from multiple centers tracked with the COLD registry. J Urol. 2008;179:397
  23. ASTRO. Consensus statement (Guidelines for PSA following radiation therapy). Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  24. Polascik TJ, Mayes JM, Mouraviev V. Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol. 2009;19:182–187
  25. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology. 2008;72:S12–S24

 Dr Polascik is a research consultant for Galil Medical.

PII: S0090-4295(09)00645-1

doi: 10.1016/j.urology.2009.02.084

Urology
Volume 74, Issue 4 , Pages 726-730 , October 2009

Article Tools

* Image Usage & Resolution